

# Melanoma Pathways: Metastatic Melanoma

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_ Treatment Start Date: \_\_\_\_\_

Pathology: \_\_\_\_\_ Stage: \_\_\_\_\_

Line of Therapy:  Adjuvant/Post-Op  1<sup>st</sup> Line  2<sup>nd</sup> Line  3<sup>rd</sup> Line  3<sup>rd</sup> Line+  
ECOG Performance Status: \_\_\_\_\_ ICD-10 Code: \_\_\_\_\_

## Biomarkers/Characteristics: (Select all that apply)

BRAF<sup>+</sup> status:  V600E Mutation positive  V600K Mutation positive  Wild Type (no mutation)  Not Reported

c-kit status:  Exon 11 Mutation Present  Exon 9 Mutation Present  No Mutation  Not Reported

### Stage IIIB/IIIC (Resected) | Adjuvant Therapy

Nivolumab (Opdivo)\*

### Metastatic Disease | First and Subsequent Lines of Therapy (1<sup>st</sup> Line+) | Any BRAF Status | ECOG PS: 0-2

Pembrolizumab (Keytruda)†

### Metastatic Disease | First Line of Therapy (1<sup>st</sup> Line) | BRAF Mutated‡ | Symptomatic Disease | ECOG PS: 0-2

Vemurafenib (Zelboraf) and cobimetinib (Cotellic)

### Metastatic Disease | Second and Subsequent Lines of Therapy (2<sup>nd</sup> Line+) | BRAF Mutated‡ | ECOG PS: 0-2

Vemurafenib (Zelboraf) and cobimetinib (Cotellic)

### Metastatic Disease | Second and Subsequent Lines of Therapy (2<sup>nd</sup> Line+) | Any BRAF Status | ECOG PS: 0-2

Ipilimumab (Yervoy)

\*Administered at a dose of 240 mg every 2 weeks or 480 mg every 4 weeks

†Administered at a dose of 2 mg/kg (up to a maximum of 200 mg).

‡BRAF mutations include V600E and V600K mutations.

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

